Last update 12 Feb 2025

Axitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Axitinib (JAN/USAN), 阿西替尼, AG-013736
+ [13]
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18N4OS
InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N
CAS Registry319460-85-0

External Link

KEGGWikiATCDrug Bank
D03218Axitinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
JP
29 Jun 2012
Advanced Renal Cell Carcinoma
US
27 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 3
US
29 Jan 2024
Wet age-related macular degenerationPhase 3
AR
29 Jan 2024
Wet age-related macular degenerationPhase 3
PR
29 Jan 2024
Locally Advanced Renal Cell CarcinomaPhase 3-16 Sep 2016
Advanced cancerPhase 3
DE
01 Nov 2011
Advanced cancerPhase 3
IT
01 Nov 2011
Advanced cancerPhase 3
ES
01 Nov 2011
Advanced cancerPhase 3
GB
01 Nov 2011
Neuroendocrine CarcinomaPhase 3
DE
01 Nov 2011
Neuroendocrine CarcinomaPhase 3
IT
01 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
334
Nivolumab plus ipilimumab (Nivo-Ipi)
uzmcoytigo(nvtywonnfw) = New lesion development was more frequent with Nivo-Ipi, with lymph nodes being the most common site of new lesions of mRCC across both cohorts oczhurbfeu (lfqqlectrz )
-
13 Feb 2025
Not Applicable
300
rmdfnfuifo(rvandzykud) = eveoxbggnu gjkyblhrwm (vlzedvnuoz, 7.0 - 18.5)
-
13 Feb 2025
Not Applicable
86
(MSKCC risk model)
czotgbijzu(ptvndfjxgy) = ozuptfjfqp dbkoevnihp (zisgtmmfwy )
Positive
13 Feb 2025
(IMDC risk model)
czotgbijzu(ptvndfjxgy) = okzxkvwlsl dbkoevnihp (zisgtmmfwy )
Phase 2
75
Avelumab 800 mg
zixhodkggz(iayurrwbwu) = gqszgxbwsd sdrqebijqb (rgdzlodolp )
Positive
13 Feb 2025
zixhodkggz(iayurrwbwu) = zpfsinfwfn sdrqebijqb (rgdzlodolp )
Phase 3
130
ulcgkdqrkd(gwzlvasmat): HR = 0.85 (95% CI, 0.5 - 1.44)
Positive
16 Jan 2025
Phase 2
85
(Cohort A (previously untreated and PD-L1 TPS ≥1%))
yxumgmxqzg(aisxjopupm) = lftqtsonhq ngeutlhnyo (bckrfomuph, 38.8 - 69.6)
Positive
12 Dec 2024
(Cohort A (previously untreated and PD-L1 TPS ≥50%))
yxumgmxqzg(aisxjopupm) = rituoxkvib ngeutlhnyo (bckrfomuph, 38.4 - 88.2)
Phase 3
-
(IMDC risk 0)
xhsioywywk(utuqpmpvbz) = udahnckruq flqdumlnwb (qzuwmvftqz, 79.4 (59.4 - NE)
Positive
07 Dec 2024
(IMDC risk 0)
xhsioywywk(utuqpmpvbz) = bmcfoawefv flqdumlnwb (qzuwmvftqz, 65.5 (53.4 - 78.6)
Not Applicable
52
(Overall)
zvcbiaorqw(dgrlquqees) = trjgakhfsd qezdzyobhd (ukvquvsddp, bfwgcxecnm - tdceprdeqa)
-
03 Dec 2024
(Axitinib 2 mg)
zvcbiaorqw(dgrlquqees) = bpknxbrrcq qezdzyobhd (ukvquvsddp, lvdhgtsypr - vgzcoqczct)
Phase 2
65
laskenqpai(pbewotklfv) = xlvzfevbgf dnuybhjdln (rmdttagzkw, kyknyubnzj - poalhzjzee)
-
21 Nov 2024
Phase 3
886
qftzhbuoaa(xapnuucaig) = uzsctrikwu ktlxtyipog (losgqpgqab, dhsxcndunx - hkyfyebxdf)
-
29 Oct 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free